Ikena Oncology
Patient-directed oncology therapies across pathways relevant in tumor and immune cells
Patient-directed oncology therapies across pathways relevant in tumor and immune cells
Ikena Oncology is a biotechnology startup founded in 2016 and headquartered in the United States. The company is dedicated to developing patient-directed oncology therapies targeting key signaling pathways driving cancer formation and spread. With a focus on scientifically validated cancer driver pathways lacking approved or effective therapies, Ikena aims to address high unmet medical needs.
The company has built a deep pipeline of wholly owned and partnered programs concentrating on genetically defined or biomarker-driven cancers, allowing them to target specific patient populations deemed most likely to respond to treatment with their product candidates. In addition, Ikena has assembled a team of drug hunters, translational researchers, clinicians, and entrepreneurs from leading biotechnology innovators and has garnered support from top-tier investors and partners, including their most recent $40.00M Post-IPO Equity investment on 15 May 2023 from H. C. Wainwright & Co.
With a strong emphasis on discovery chemistry, translational science, and patient-centric drug development, Ikena Oncology is poised to advance and expand its portfolio of novel, patient-directed oncology therapies, positioning itself as a significant player in the ever-evolving biotechnology and healthcare industry.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Equity | $40.00M | 1 | H. C. Wainwright & Co. | 15 May 2023 |
| Series B | $120.00M | 9 |
|
05 Jan 2021 |
| Series A | $49.00M | - | 14 Dec 2017 |
No recent news or press coverage available for Ikena Oncology.
We care about your data, and we'd love to use cookies make your experience better.
